Literature DB >> 9637203

Visual improvement during octreotide therapy in a case of episellar meningioma.

M L Jaffrain-Rea1, G Minniti, A Santoro, S Bastianello, G Tamburrano, A Gulino, G Cantore.   

Abstract

Meningiomas of the tuberculum sellae can induce compression of the optic tract. We report the case of a 54-year-old female patient affected by a suspected pituitary macroadenoma with severe visual field defects, who experienced a significant clinical and visual improvement during short-term octreotide therapy, contrasting with the lack of neuroradiological evidence for tumor shrinkage. The patient subsequently underwent transcranial surgery with a final diagnosis of meningioma. The putative mechanisms of visual improvement during octreotide therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637203     DOI: 10.1016/s0303-8467(97)00110-8

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

Review 1.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

Authors:  Thomas Kaley; Igor Barani; Marc Chamberlain; Michael McDermott; Katherine Panageas; Jeffrey Raizer; Leland Rogers; David Schiff; Michael Vogelbaum; Damien Weber; Patrick Wen
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

2.  Value of petrosal sinus sampling: coexisting acromegaly, empty sella and meningioma.

Authors:  S Yarman; O Minareci
Journal:  Neuroradiology       Date:  2004-12-04       Impact factor: 2.804

3.  Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships?

Authors:  E De Menis; G Tulipano; S Villa; D Billeci; C Bonfanti; P Pollara; P Pauletto; A Giustina
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

4.  Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.

Authors:  John R Lindsay; Janet A Harding; Peter K Ellis; Brian Sheridan; A Brew Atkinson
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.